Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid…
$155.94-0.46%
报价 2026-11-06
市值
$20.89B
EV
$40.29B
PE (TTM)
129.2x
预期 PE (FY2026)
8.5x
52 周区间距高点 -67.1%
$155.94$473.29
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | $20.89B | -0.5% | +49.7% | 81.7% | 129.2x | 85.2x | 44.7x | |
| REGNRegeneron Pharmaceuticals, Inc. | $93.54B | +0.2% | +11.7% | 85.8% | 19.8x | 15.1x | 26.6x | |
| CICigna Corporation | $77.58B | -2.6% | +4.5% | 9.5% | 11.7x | 7.8x | 9.2x | Cheap |
| CORCencora, Inc. | $63.65B | -1.8% | +4.5% | 4.3% | 23.2x | 13.6x | 15.1x | |
| CAHCardinal Health, Inc. | $62.92B | +1.5% | +3.9% | 4.3% | 31.6x | 16.9x | 11.9x | |
| EWEdwards Lifesciences Corporation | $58.87B | +1.3% | +11.8% | 78.1% | 44.5x | 32.6x | 44.1x | GARP |
| ARGXargenx SE | $58.31B | +3.6% | – | 89.9% | 38.2x | 39.0x | 58.5x | |
| BDXBecton, Dickinson and Company | $57.71B | -0.8% | +2.4% | 45.8% | 25.3x | 14.7x | 17.3x | |
| IDXXIDEXX Laboratories, Inc. | $53.26B | +0.8% | +10.7% | 62.9% | 45.6x | 32.3x | 41.0x | |
| 同行中位数 | – | – | +4.5% | 54.4% | 28.5x | 16.0x | 21.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。